软件服务 66家，占比约31%，为排队企业最多的行业。 主板上市主导 42宗新股中，主板上市占比超95%。 截至6月30日，仍在递表有效期的公司达211家，其中首次递表企业占比超80%，行业集中在科技、新消费和医药医疗领域。 医疗保健 40家，占比约19%，生物科技公司占比突出。 行业分布 工业制造 31家，占比约15%，涵盖智能制造、物流机器人等领域。 其他行业 包括消费、金融、能源等，分布较为分散。 A股企业赴港热潮 超180家A股企业排队港股IPO，包括立讯精密等"果链三巨头"，以及分拆自A股的科技、医药子公司。 截至2025年6月30日，仍在递表有效期内的公司，详细名单如下（来源公众号，活报告）。 | 25/6/30 | 主板 | | 未曾体 | 华泰金融 | | --- | --- | --- | --- | --- | | 25/6/30 | 主板 | 1 | 软件服务 | 农银国际 | | 25/6/30 | 主板 | 1 | 贵金属 | 摩根士丹利、中信证券 | | 25/6/30 | 主板 | 1 | 工业制造 | 中信证券 | | 25/6/30 | 主板 | 1 | 汽车 | 中信证券、 ...

港股也继续上涨，涨幅比A股高一些。 港股科技股领涨。 文 | 银行螺丝钉 （转载请注明出处） 本周A股港股都比较强势，周五继续上涨。 截止到收盘，还在4.8星，距离4.7星不远。 大盘股上涨略多，中小盘股微涨。 价值、成长风格都上涨。 消费、科技等比较强势。 随着上涨，低估品种也在逐渐减少。 市场上还有一些低估品种，例如自由现金流类、质量类等等。 后面也会挑选一些不错的指数加入估值表。 但整体上，越是下跌，投资机会越多； 越是上涨，投资机会越少。 机会是跌出来的，风险是涨出来的。 1. 港股今年比较强势。 每个时间段都有发力的品种。 春节后，先是港股互联网公司大幅上涨，当时有Deepseek带来的AI行情。 之后是港股消费，以泡泡玛特、老铺黄金、蜜雪冰城为代表的新消费。 再之后是红利指数，港股红利、沪港深红利低波动上涨。 到了最近，港股医药指数大幅上涨。 2. 港股其实前两年有过大幅低迷的阶段。 2021-2022年，港股是全球下跌幅度最大的市场之一。 当时几个负面因素叠加在一起： ·美联储大幅加息，全球流动性收紧。 这几个领域也成为今年港股表现最好的几个板块之一。 港股一些品种，出现了"盈利上涨+估值提升" ...

点击查看公告原文>> 来源：新浪港股-好仓工作室 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 2025 年 7 月 18 日，嘉鼎国际集团（股份代号：08153）公告称，通过一般授权以"配售新股份"方式融 资，配售最多 18,341,363 股（约 0.2 亿股），募集约 0.1 亿港元，所得款项净额约 138 万港元（假设配 售股份获悉数配售及扣除一切有关开支后）。本次融资由昌利证券担任配售代理。 配售新股份配售价 0.081 港元，较 2025 年 7 月 18 日收市价 0.10 港元折让约 19%，较前五个交易日平 均收市价 0.0774 港元溢价约 4.65%。配售股份占公司于公告日期全部已发行股本 366,827,260 股股份的 ...

农林牧渔/动物保健Ⅱ 生物股份（600201.SH） 非瘟亚单位疫苗临床试验获批，创新龙头成长动能强 2025 年 07 月 18 日 投资评级：买入（维持） | 日期 | 2025/7/17 | | --- | --- | | 当前股价(元) | 9.53 | | 一年最高最低(元) | 9.53/5.62 | | 总市值(亿元) | 106.77 | | 流通市值(亿元) | 106.77 | | 总股本(亿股) | 11.20 | | 流通股本(亿股) | 11.20 | | 近 3 个月换手率(%) | 156.32 | 股价走势图 -20% 0% 20% 40% 60% 2024-07 2024-11 2025-03 生物股份 沪深300 数据来源：聚源 相关研究报告 《业绩短期承压，持续创新厚积薄发 —公司信息更新报告》-2025.4.27 《业绩短期承压，新品储备充足持续 成长—公司信息更新报告》-2024.11.3 《业绩韧性十足创新驱动发展，新品 多点开花持续成长—公司信息更新报 告》-2024.9.1 陈雪丽（分析师） 王高展（分析师） chenxueli@kysec.cn 证书编号：S0 ...

普莱柯：公司获得新兽药注册证书 智通财经7月18日电，普莱柯(603566.SH)公告称，公司与其他单位联合申报的"鸡新城疫、传染性支气 管炎二联耐热保护剂活疫苗（LaSota株+SZ160株）"为新兽药，并于2025年7月17日公示了核发《新兽 药注册证书》。该新兽药采用的毒株SZ160株为流行QX型毒株的驯化致弱株，具有高繁殖性能、高安 全性、快速免疫起效和长免疫持续期等特点，可有效防控目前国内流行的鸡传染性支气管炎疫病。该产 品上市将丰富公司禽用疫苗产品品类，提升市场竞争力，并为公司带来新的业绩增长点。 ...

嘉必优公告，2025年半年度实现营业收入约3.07亿元，较上年同期增长17.59%；归属于母公司所有者的 净利润约1.07亿元，较上年同期增长57.61%；归属于母公司所有者的扣除非经常性损益的净利润约9300 万元，较上年同期增长75.45%。报告期内公司营业收入增加主要系核心产品ARA和藻油DHA销量增加 所致；利润增加主要系营业收入增加，同时公司生产效率提升，叠加产品结构和客户结构优化，提升了 公司的盈利能力。 ...

Investment Rating - The report provides a positive investment rating for the health supplement industry, particularly highlighting the growth potential of the HMB segment and the overall market expansion [4][28]. Core Insights - The report emphasizes that the global dietary supplement industry is experiencing continuous expansion, with the market size expected to approach $200 billion by 2025, driven by increasing health awareness among consumers [28]. - The company, as the largest global supplier of HMB, is well-positioned to benefit from the growing demand for muscle health products, with a projected revenue increase of 22.8% in 2024 [49][60]. - The report also notes the company's strong partnerships with major clients like Abbott, which significantly contribute to its revenue, particularly in the HMB segment [55][111]. Financial Performance - The company achieved a revenue of 1.0 billion yuan in 2024, reflecting a year-on-year growth of 12.3% [3][7]. - The net profit attributable to shareholders reached 174.4 million yuan in 2024, with a compound annual growth rate (CAGR) of 16.7% from 2021 to 2024 [7][21]. - The gross margin improved to 43.5% in 2024, while the net margin slightly decreased to 17.5% due to a minor increase in expenses [21][22]. Revenue Breakdown - In 2024, the revenue from nutritional raw materials and formulations was 6.5 billion yuan and 3.5 billion yuan, respectively, accounting for 64.6% and 35.1% of total revenue [12][96]. - The HMB segment generated 2.93 billion yuan in revenue in 2024, representing 45.3% of the nutritional raw materials revenue [49][85]. - The company’s international sales are significant, with the U.S. accounting for 30.6% of revenue, indicating a strong presence in overseas markets [15]. Market Trends - The global sports nutrition market is projected to grow at a CAGR of 4.5% from 2020 to 2026, with HMB being a key ingredient driving this growth [33][35]. - The joint health supplement market, including glucosamine and chondroitin sulfate, is expected to maintain a steady growth rate of 5.8% from 2020 to 2027, supported by an aging population [39][41]. - The report highlights the increasing penetration of contract manufacturing in the health supplement industry, with a market size exceeding 100 billion yuan [45]. Production Capacity and Utilization - The company’s production capacity for HMB, glucosamine, and chondroitin sulfate is expected to exceed 90% utilization in 2024, indicating strong demand [117]. - The company plans to invest 210 million yuan to expand its production capacity for HMB and other nutritional raw materials, which will enhance its ability to meet growing market demands [117][120].

Group 1: Company Overview - The company primarily engages in the research, production, and sales of nutritional health foods (including raw materials and finished products) and feed additives [2][3] - The production of health food raw materials and feed additives mainly occurs domestically, with a high export ratio; finished health food products are primarily produced and sold overseas, showing significant growth through cross-border e-commerce [3] Group 2: Product Development and Market Position - The company utilizes synthetic biology as a foundational technology for large-scale production of various raw materials, including Coenzyme Q10, NMN, NADH, Vitamin K2, and others [3] - Coenzyme Q10 holds the largest global market share, demonstrating notable cost and scale advantages [3] - The company aims to reduce production costs for products like astaxanthin, DHA, and EPA to enhance market competitiveness [3] Group 3: Brand and Sales Strategy - The company owns two major health food brands, Doctor's Best and Zipfizz, with production capabilities for capsules, tablets, and powders [3][4] - Doctor's Best is a well-known health brand in North America, showing steady growth, while Zipfizz maintains stable performance with new products developed for the U.S. market [4] - The marketing strategy for domestic health food business focuses on market insights, product strategy, resource integration, and data-driven upgrades to create market-leading products [4] Group 4: Financial Performance - The company's performance growth in the first half of 2025 is primarily attributed to increased sales of Coenzyme Q10, vitamins, and domestic health products [3]

Core Viewpoint - The Hong Kong stock market saw a collective surge in the pharmaceutical and biotechnology sector, with notable gains in companies like Li Auto and China Biologic Products [2][4][12]. Group 1: Market Performance - The Hang Seng Index closed at 24,498.95 points, down 0.08%, while the Hang Seng Tech Index rose by 0.56% to 5,448.85 points [2]. - The total market turnover was HKD 236.4 billion, a decrease from the previous trading day, with net inflows from southbound funds amounting to HKD 1.855 billion [2]. - Among the constituent stocks, 43 rose and 40 fell, with Li Auto leading the gains at 9.73% [4]. Group 2: Notable Stock Movements - Li Auto's stock price increased by 9.73%, closing at HKD 124.10, with a year-to-date increase of 32.09% [5][19]. - China Biologic Products rose by 5.90%, with a significant year-to-date increase of 114.68% [5]. - The pharmaceutical sector saw a strong performance, with the Wande Pharmaceutical and Biotechnology Index rising by 4.65% [15]. Group 3: Sector Analysis - The healthcare sector increased by 5.17%, while the materials and energy sectors experienced declines of 1% and 0.94%, respectively [6]. - The CAR-T index rose by 8.19%, and the unprofitable biotech index increased by 6.28%, indicating strong investor interest in these areas [9]. Group 4: Regulatory Developments - The National Healthcare Security Administration and the National Health Commission introduced measures to support the high-quality development of innovative drugs, which is expected to enhance the role of commercial insurance in the multi-level medical security system [17]. - This regulatory change is anticipated to positively impact the upstream supply chain, including research reagents and CXO industries, with expected performance improvements starting from mid-2025 [17]. Group 5: Company-Specific News - Li Auto announced the opening of pre-orders for its i8 model, leading to a stock price increase of nearly 10% [18][19]. - The expected price range for the i8 is between RMB 350,000 and RMB 400,000, with the official price to be announced on July 29 [22].

面对复杂多变的国际环境，世界不仅没有与中国脱钩，反而更加依赖中国。 对中国外贸人而言，"十四五"时期无疑是一场严峻的大考。全球疫情与贸易摩擦的双重冲击，构成了前 所未有的复杂变局。 然而，在这风云激荡的5年里，危机与机遇并存——外贸不仅上演了亮眼开局，而且全球市场对中国制 造业的依赖有增无减。 公开数据显示，目前中国制造业增加值占全球30%以上，总体规模连续15年保持全球第一。根据联合国 发布的《工业化的未来》报告，中国的工业产值预计将在2030年占全球总量的45%。 "对外贸易的增长根本上取决于一个国家的生产力，一旦生产力够强、效率够高，这个国家能为全球提 供产品的能力就越强，这将形成一个趋势。"上海社科院经济研究所研究室主任、研究员詹宇波告诉第 一财经，中国制造业在全球市场的占比不断提升，说明大家对中国参与全球分工、扩大对外贸易规模是 有共识的。 面对复杂多变的国际环境，世界不仅没有与中国脱钩，反而更加依赖中国。对外经济贸易大学中国 WTO研究院院长、教授屠新泉对第一财经表示，中美之间的直接依赖程度下降，但间接依赖程度却在 提高，因为中国产业链与第三方国家或地区的合作关系越来越紧密。因此，从增加值来看，美 ...